Back
ESC Professional Premium Access

Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study

Session: Chronic heart failure - Pharmacotherapy
Topic: Pharmacotherapy
Speaker: Professor G. Savarese (Stockholm, SE)
Event: ESC Congress 2022

Congress Presentation

About the speaker

Professor Gianluigi Savarese

Karolinska Institute, Stockholm (Sweden)
53 presentations
10 followers

4 more presentations in this session

Direct effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial

Speaker: Doctor C. Andersen (Herlev, DK)

Access
Abstract
Slides
Thumbnail

Acute effect of empagliflozin on serum uric acid - a subanalysis of the EMPAG-HF trial (effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure)

Speaker: Mr J. Bogoviku (Jena, DE)

Access
Abstract
Slides
Thumbnail

Real-world eligibility and cost-effectiveness analysis for empagliflozin in patients with heart failure

Speaker: Doctor E. Kim (Daejeon, KR)

Access
Abstract
Slides
Thumbnail

Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial

Speaker: Professor M. Boehm (Homburg, DE)

Access
Abstract
Slides
Thumbnail

Access the full session

Chronic heart failure - Pharmacotherapy

Speakers: Professor G. Savarese, Doctor C. Andersen, Mr J. Bogoviku, Doctor E. Kim, Professor M. Boehm
Access
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb